XTalks

MARCH 31, 2023

By growing high quality crystal structures of protein-based therapeutics under microgravity, researchers can gain better insights into their complex structures and stability. This can help guide better drug formulations, delivery of higher therapeutic doses and improved biomanufacturing processes.

Protein 97

Protein Research Development Manufacturing 97

pharmaphorum

MAY 12, 2021

UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to get in on the action. . The post Lilly buys into MiNA’s protein-boosting RNA tech in $1.25bn deal appeared first on.

RNA 76

RNA Protein Drugs Pharma Companies 76

XTalks

FEBRUARY 29, 2024

Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. At the helm of this venture is Dr. Taylor H. How is your lead program differentiated?

Protein 94

Protein Development Clinical Trials Clinical Trials 94

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 1.351 variant.

Protein 97

Protein Vaccination Vaccine Trials 97

Pharmaceutical Technology

JUNE 21, 2023

In the past year, Hemgenix has been granted approval by the US Food and Drug Administration (FDA) and has received conditional marketing authorisation from the European Commission (EC) and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

Gene Therapy 246

Gene Therapy Gene Protein Sales 246

Pharmaceutical Technology

FEBRUARY 14, 2023

It will also support smaller dose vials development, selection of strain as per the US Food and Drug Administration (FDA) recommendations, and transition to the commercial market. The company stated that the deal would maintain the access of the US public to its vaccine.

Vaccination 162

Vaccination Vaccine Protein Engineer 162

pharmaphorum

SEPTEMBER 16, 2022

Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares. Verily’s Immune Profiler platform is “a discovery engine consisting of proprietary immune profiling lab workflow, growing multi-omic database, and advanced analytical tools”.

Development 135

Development Research Drugs Clinical Trials 135

Pharmaceutical Technology

APRIL 20, 2023

Biopharmaceutical company Abdera Therapeutics has raised $142m in combined Series A and B financing to engineer and advance antibody-based radiopharmaceuticals to treat cancer. The company’s lead programme is aimed at delta-like ligand 3 (DLL3), which is a protein in the Notch pathway.

Antibody 130

Antibody Engineer Protein Drugs 130

Pharmaceutical Technology

OCTOBER 12, 2022

Under the collaboration deal, Nimbus will develop isoform-selective small molecule AMPK activators to potentially treat several metabolic diseases using its computational drug discovery engine and structure-based drug design knowledge. These proteins have proven to be challenging for drug developers to tackle.

Development 130

Development Protein Engineer Drugs 130

Pharmaceutical Technology

FEBRUARY 13, 2023

Although recently approved drugs can treat seizures more safely, they do not treat the comorbidities that patients experience. Rather than replacing mutated genes with functional copies, STK-001 promotes protein production in the healthy copy of the SCN1a gene. Some newly approved drugs have improved the situation.

Research 264

Research Gene Gene Therapy Genome 264

Pharmaceutical Technology

APRIL 28, 2023

Generate Biomedicines has signed a co-development and commercialisation agreement with the University of Texas MD Anderson Cancer Center to expedite the development of new protein therapeutics for oncology using generative AI. TRACTION is a part of the therapeutics discovery division of MD Anderson.

Development 130

Development Clinical Trials Clinical Trials Protein 130

Pharmaceutical Technology

MAY 4, 2023

Originated by the company’s in-house discovery engine, ATX-01 is designed to target microRNA 23b (miR-23b), a pathogenic gene associated with regulating the muscleblind-like protein (MBNL) expression involved in DM1. It has a dual mechanism of action that targets toxic dystrophia myotonica protein kinase and MBNL protein.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Protein 130

pharmaphorum

NOVEMBER 26, 2020

The headline news in the new agreement is the formation of a joint AI Innovation Lab – split between InstaDeep’s headquarters in London in the UK and BioNTech’s site in Mainz Germany – that will focus on drug discovery and design, protein engineering, manufacturing and supply chain.

Research 105

Research Protein Engineer Manufacturing 105

pharmaphorum

DECEMBER 24, 2020

A serotonin sensor designed using Artificial Intelligence (AI) could help scientists study sleep and mental health and potentially find new neurology drugs. The US National Institutes of Health said that the research it had co-funded used AI to transform a bacterial protein into a new research tool.

Development 77

Development Drugs Protein Genetic Engineering 77

Scienmag

OCTOBER 27, 2020

Scientists from the iMolecule group at Skoltech Center for Computational and Data-Intensive Science and Engineering (CDISE) developed BiteNet, a machine learning (ML) algorithm that helps find drug binding sites, i.e. potential drug targets, in proteins. BiteNet can analyze 1,000 protein structures in 1.5

Drugs 59

Drugs Protein Engineer Scientist 59

pharmaphorum

NOVEMBER 5, 2021

Google parent Alphabet has drawn on its DeepMind artificial intelligence division to form a drug discovery unit that it calls Isomorphic Labs. That raised the hope that it could be used accelerate research into how diseases affect the body, and develop new medicines that can latch onto troublesome proteins effectively. Demis Hassabis.

Drugs 72

Drugs Protein Genome Genomics 72

pharmaphorum

APRIL 8, 2022

Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 At the American Society of Haematology (ASH) meeting last December, the biotech presented data showing that the drug could halt the growth of tumours, with the effects lasting beyond the treatment phase. billion in development, regulatory and commercial milestones.

Drugs 105

Drugs Immune Response Licensing Licensing 105

XTalks

NOVEMBER 8, 2024

Top Hospital-Based Healthcare Innovations Google DeepMind AlphaFold 3: Rendering Molecules in HD Drug discovery often hinges on predicting how proteins interact with each other. Using Ada’s advanced medical engine, users receive personalized health insights and referrals to the right level of care.

Doctors 104

Doctors Doctor Protein Nurses 104

Scienmag

NOVEMBER 17, 2020

Scientists have established a new method to image proteins that could lead to new discoveries in disease through biological tissue and cell analysis and the development of new biomaterials that can be used for the next generation of drug delivery systems and medical devices.

Protein 67

Protein Drug Delivery Systems Drug Delivery Scientist 67

Scienmag

FEBRUARY 23, 2021

(February 23, 2021) – The Gates Biomanufacturing Facility (GBF) has completed the manufacturing and release of a protein-based biologic under Good Manufacturing Practice for Phase 1 Investigational Drugs for first-in-human clinical trials.

Protein 57

Protein Manufacturing Clinical Trials Clinical Trials 57

Roots Analysis

SEPTEMBER 9, 2024

Over the years, pharmaceutical companies have shifted their priorities from traditional interventions towards more advanced pharmacological strategies, such as protein therapeutics. Further, $400 billion is the anticipated sales of protein-based therapeutics in 2023. The mRNA is then translated into to form functional proteins.

Protein 40

Protein Gene Production DNA 40

pharmaphorum

AUGUST 9, 2022

AI could address the most significant issue in drug discovery, finds Ben Hargreaves, and also offers the potential to use tissue samples to create precision medicine for specific patient groups. An area that offers hope to accelerate an understanding of cancer and speed up drug development is artificial intelligence.

Drugs 111

Drugs Doctors Doctor Pharma Companies 111

Pharmaceutical Technology

JUNE 4, 2023

There are two main genes in the AAV genome, rep and cap, which encode nine different proteins. Transcription of the rep gene is initiated from the p5 or p19 promoters to, respectively, produce the large (Rep78 and Rep68) and small (Rep52 and Rep40) nonstructural Rep proteins.

Gene 262

Gene Gene Therapy Genetics DNA 262

The Pharma Data

DECEMBER 22, 2020

SAITAMA, Japan–( BUSINESS WIRE )– After a capital increase in the initial closing of its series A round, with investments by Mitsubishi UFJ Capital and Real Tech Fund , Epsilon Molecular Engineering Inc. The bio industry has progressed to a point where it deals with proteins from an engineering perspective.

Engineer 52

Engineer Drugs Protein Antibody 52

The Pharma Data

MAY 19, 2023

HIGH SCHOOL SCIENTISTS AND ENGINEERS WIN NEARLY $9 MILLION AT THE REGENERON INTERNATIONAL SCIENCE AND ENGINEERING FAIR 2023 Regeneron Pharmaceuticals, Inc. ” Regeneron ISEF provides a global stage for the best and brightest young scientists and engineers around the world.

Engineer 52

Engineer Scientist Protein Research 52

Pharmaceutical Technology

MARCH 2, 2023

According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Povetacicept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Protein 100

Protein Engineer Drugs Clinical Trials 100

pharmaphorum

OCTOBER 14, 2022

Glick, said the company is innovating “next generation therapeutics by marrying a powerful drug discovery engine integrating machine learning [ML], biology, and medicinal and structural chemistry with an exceptional leadership of proven drug developers”. There is also a functional genomics platform for novel target discovery.

Engineer 105

Engineer Medicine Genome Genomics 105

Pharmaceutical Technology

APRIL 13, 2023

Clinical-stage biopharmaceutical firm Alentis Therapeutics has raised $105m in a Series C financing round for advancing transformational medicines targeting the CLAUDIN-1 protein. ALE.F02 is being developed for the treatment of advanced kidney, lung and liver fibrosis while ALE.C04 is a potential treatment to target CLDN1-positive tumours.

Medicine 130

Medicine Development Antibody Engineer 130

XTalks

AUGUST 17, 2020

With several biologics in the pipeline, including one in early stage clinical trials for head and neck cancer, the company is positioned to engineer highly specific biologics against immune targets in the body. protein-based biologics) and vaccine treatments. protein-based biologics) : are those which bind to specific components (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

Pharmaceutical Technology

MARCH 23, 2023

Seagen specialises in developing antibody-drug conjugates (ADCs) which will complement Pfizer’s oncology portfolio. Seagen will maintain its operations in the Seattle area and will leverage Pfizer’s protein-engineering capabilities to develop next-generation biologics.

Licensing 147

Licensing Licensing Sales Trials 147

Pharmaceutical Technology

MARCH 14, 2023

It is a pioneer in antibody-drug conjugates (ADCs) technology. The deal will also use the protein engineering and medicinal chemistry capabilities of Pfizer to advance Seagen’s ADC technology to unlock next-generation biologics and potential new target combinations.

Antibody 130

Antibody Medicine Engineer Protein 130

Scienmag

OCTOBER 12, 2020

Potential new antibiotics work by disrupting bacterial membrane and summoning immune cells in animal models PHILADELPHIA–A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has engineered powerful new antimicrobial molecules from toxic proteins found in wasp venom.

Bacteria 40

Bacteria Engineer Scientist Medicine 40

Pharmaceutical Technology

JUNE 1, 2023

Pneumagen has raised £8m ($10 million) for the further development of its intranasal antiviral drug neumifil in Phase II studies for chronic obstructive pulmonary disease (COPD) patients suffering from virus-induced exacerbations. Neumifil consists of an engineered carbohydrate-binding module domain of a Streptococcus pneumoniae protein.

In-Vitro 130

In-Vitro Engineer Protein Vaccine 130

pharmaphorum

NOVEMBER 23, 2021

The French drugmaker has been enticed by an artificial intelligence (AI) algorithm developed by Chinese tech giant Baidu, which controls most of China’s search engine traffic and is sometimes referred to as the country’s Google. billion earlier this year.

Licensing 105

Licensing Licensing Vaccination Vaccine 105

The Pharma Data

MARCH 23, 2022

Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. Drugs that target polymerase could potentially treat Ebola virus infections and save lives. The researchers discovered that Ebola virus polymerase hijacks a cellular protein called GSPT1. Catching polymerase in the act.

Protein 52

Protein Genome Genomics Research 52

Scienmag

JANUARY 3, 2022

Membrane-associated proteins play a vital role in a variety of cellular processes, yet little is known about the membrane-association mechanism. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is one such protein with an important role in cardiovascular health, but its mechanism of action on the phospholipid membrane was unknown.

Protein 80

Protein Drugs Research Engineer 80

Cloudbyz

MARCH 5, 2024

In the intricate dance of drug discovery and development, two protagonists emerge as the cornerstones of modern medicine: biologics and small molecules. Biologics: Biologics are large, complex molecules, often proteins, that are produced using living cells. The production process is often less complex compared to biologics.

Development 97

Development Drugs Immune Response Manufacturing 97